secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0001193125-24-010227
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology cuts workforce 35%, focuses on IK-930/595; BMS declines opt-in on two programs
--------------------------------------------------------------------------------

- Workforce reduction of ~35% (approx. 20 employees) to focus on clinical programs IK-930 and IK-595.
- Cash, cash equivalents and marketable securities ~$175M as of Dec 31, 2023 (unaudited); runway extended into 2H 2026.
- Bristol Myers Squibb declined opt-in for IK-175 program; also did not opt-in for IK-412; full rights returned to Ikena.
- IK-930 optimized formulation now in clinic; clinical data update planned for 2H 2024.
- IK-595 first cohort dosed and cleared safety evaluation window; enrollment in RAS/RAF mutant patients ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/0001193125-24-010227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/d459979d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-010227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer